Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET.
Interested parties can attend the live webcast for the event by registering on the Events and Presentation section of the company’s Investor Relations webpage. A webcast replay will be available beginning September 19, 2023, at 12:00 p.m. PT / 3:00 p.m. ET.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers in the U.S., and value-added services including the OPUL® Relational Commerce platform for aesthetic practices.
Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.
Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif. Learn more www.revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, www.hcp.daxxifytherapy.com, or connect with us on LinkedIn.
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822424203/en/
Contacts
Investors
Revance Therapeutics, Inc.:
Jessica Serra, 510-279-6886
jessica.serra@revance.com
or
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
laurence@gilmartinir.com
Media
Revance Therapeutics, Inc.:
Sara Fahy, 949-887-4476
sfahy@revance.com
